Teladoc Health Inc. (TDOC) saw its stock soar 5.20% during intraday trading on Thursday, following the announcement of a pharmacy integration agreement with Eli Lilly's LillyDirect pharmacy partner, Gifthealth. This agreement will provide Teladoc Health members enrolled in its Comprehensive Weight Care Program with access to the FDA-approved obesity drug Zepbound® (tirzepatide) through a self-pay option.
The integration with Gifthealth allows eligible Teladoc Health members without insurance coverage for glucagon-like peptide-1 receptor agonists (GLP-1s) for obesity to have single-use Zepbound® vials delivered directly to their homes. This move aims to reduce barriers to high-quality care and help members afford transformative FDA-approved treatments while avoiding the potential risks of compounded medications.
In addition to clinically appropriate medication access, Teladoc Health's Comprehensive Weight Care Program offers a multi-disciplinary, evidence-based approach with support from licensed clinicians, registered dietitians, and expert health coaches. Members receive personalized lifestyle coaching, nutrition counseling, mental health support, and proven behavior change resources to help manage and maintain a healthy weight.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。